Former Food and Drug Administration Commissioner Scott Gottlieb said Sunday that the 1.7 million doses of Merck antiviral COVID-19 treatment purchased by the U.S. the beginning of this year “is not enough.”
Gottlieb stated on CBS’s “Focus on the World” that “1.7 million, through a sign that these alternatives will be approved, covers us with a month in which the Delta has been … to the south.
“So, I think there can be a little speculation in trying to get more production in place and get more doses,” Gottlieb added.
He explained that Strategic National Stockpile had between 50 million and 80 million medical courses in the event of a flu outbreak, on average.
“It’s not enough,” @ScottGottliebMD states that of the 1.7 million new Merck pill COVID-19 pill purchased by the US government.
He says that by comparison, the national database contains between 50 and 80 million courses for the treatment of influenza. pic.twitter.com/FjVZTkzNMO
– Face the World (@FaceTheNation) October 3, 2021
Gottlieb added that Merck’s medical treatment is likely to happen.
“I would expect to see a program similar to the one we have with anti-retroviral drugs that will be distributed to the provinces,” Gottlieb told Brennan.
Earlier this summer, Biden’s management announced it would be buying 1.7 million courses of Merck’s antiviral COVID-19 treatment, called molnupiravir.
Merck said last week a third phase of trials showed that oral treatment was effective in treating COVID-19. Merck reported that experimental data showed that 7.3 percent of those who received treatment were hospitalized within 29 days compared to 14.1 percent of people who were given placebo and hospitalized or died after the trial.